Inventor · disambiguated record
Justin Andrew Caravella
Also filed as: CARAVELLA JUSTIN · CARAVELLA JUSTIN A · CARAVELLA JUSTIN ANDREW
48 granted patents·23 pending applications·368 citations·filing 2006–2025
98Inventor score
Files withFORMA THERAPEUTICS INC32FORMA TM2 INC7NIMBUS WADJET INC6BIOGEN MA INC4CAMP4 THERAPEUTICS CORP4
Top patents by PatentIndex Score
71 records- 0198US10550098B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·17 cites·25 claims
- 0298US10414752B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·19 cites·20 claims
- 0398US9834539B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Dec 5, 2017·28 cites·108 claims
- 0498US9624175B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·25 cites·39 claims
- 0598US9624216B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·26 cites·74 claims
- 0697US11498913B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2020·Granted Nov 15, 2022·4 cites·18 claims
- 0797US9771349B2Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Sep 26, 2017·27 cites·68 claims
- 0896US10005734B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Jun 26, 2018·25 cites·75 claims
- 0996US9902728B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Feb 27, 2018·24 cites·40 claims
- 1096US9815817B2Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Nov 14, 2017·24 cites·48 claims
- 1195US10934299B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Mar 2, 2021·7 cites·20 claims
- 1295US10889567B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Jan 12, 2021·5 cites·21 claims
- 1395US10377760B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·17 cites·20 claims
- 1495US10280150B2Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2017·Granted May 7, 2019·19 cites·2 claims
- 1595US10266495B2Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2018·Granted Apr 23, 2019·19 cites·9 claims
- 1695US10253015B2Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2018·Granted Apr 9, 2019·20 cites·12 claims
- 1794US10294206B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2015·Granted May 21, 2019·7 cites·16 claims
- 1892US11053305B2Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptideQ32 BIO INC·Filed 2020·Granted Jul 6, 2021·6 cites·35 claims
- 1992US10577329B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Mar 3, 2020·4 cites·20 claims
- 2091US10407419B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Sep 10, 2019·5 cites·5 claims
- 2190US11814386B2Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitorsFORMA THERAPEUTICS INC·Filed 2022·Granted Nov 14, 2023·1 cites·20 claims
- 2288US11247987B2Inhibiting ubiquitin specific peptidase 30FORMA THERAPEUTICS INC·Filed 2018·Granted Feb 15, 2022·3 cites·24 claims
- 2388US11053306B2Fusion protein constructs comprising anti-C3d antibody and factor HQ32 BIO INC·Filed 2020·Granted Jul 6, 2021·2 cites·28 claims
- 2488US10550099B2Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·4 cites·15 claims
- 2587US12275715B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2023·Granted Apr 15, 2025·0 cites·23 claims
- 2687US10807976B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Oct 20, 2020·2 cites·18 claims
- 2784US11535618B2Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Dec 27, 2022·2 cites·21 claims
- 2883US10889592B2Thienopyrazine carboxamides as ubiquitin-specific protease inhibitorsVALO EARLY DISCOVERY INC·Filed 2017·Granted Jan 12, 2021·2 cites·28 claims
- 2983US10399980B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 3, 2019·2 cites·11 claims
- 3083US10189841B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Jan 29, 2019·3 cites·11 claims
- 3183US2023125739A1Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3282US11524966B1Carboxamides as ubiquitin-specific protease inhibitorsVALO EARLY DISCOVERY INC·Filed 2018·Granted Dec 13, 2022·2 cites·15 claims
- 3381US11161848B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 2, 2021·1 cites·26 claims
- 3480US10913753B2Thienopyridine carboxamides as ubiquitin-specific protease inhibitorsFORMA THERAPEUTICS INC·Filed 2017·Granted Feb 9, 2021·2 cites·20 claims
- 3580US9902775B2Anti-blood dendritic cell antigen 2 antibodies and uses thereofBIOGEN MA INC·Filed 2013·Granted Feb 27, 2018·6 cites·53 claims
- 3679US2025034136A1Wrn inhibitorsNIMBUS WADJET INC·Filed 2024·Application pending·0 cites
- 3778US2024132499A1Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitorsFORMA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3875US12319916B2Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAsCAMP4 THERAPEUTICS CORP·Filed 2024·Granted Jun 3, 2025·0 cites·15 claims
- 3975US12043623B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2021·Granted Jul 23, 2024·0 cites·20 claims
- 4074US9738707B2Heterodimeric Fc regions, binding molecules comprising same, and methods relating theretoTAYLOR FREDERICK R·Filed 2012·Granted Aug 22, 2017·2 cites·33 claims
- 4174US7960552B2Farnesoid X receptor agonistsGLAXOSMITHKLINE LLC·Filed 2007·Granted Jun 14, 2011·3 cites·6 claims
- 4272US12018030B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsVALO HEALTH INC·Filed 2021·Granted Jun 25, 2024·0 cites·16 claims
- 4371US9567391B2JCV neutralizing antibodiesBIOGEN IDEC INC·Filed 2013·Granted Feb 14, 2017·2 cites·24 claims
- 4471US2020115343A1Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4570US12421233B2WRN inhibitorsNIMBUS WADJET INC·Filed 2025·Granted Sep 23, 2025·0 cites·20 claims
- 4670US12344609B2WRN inhibitorsNIMBUS WADJET INC·Filed 2025·Granted Jul 1, 2025·0 cites·26 claims
- 4768US11879008B2Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulatorQ32 BIO INC·Filed 2021·Granted Jan 23, 2024·0 cites·32 claims
- 4867US2022185806A1Inhibiting ubiquitin specific peptidase 30FORMA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4965US2025304700A1Anti-blood dendritic cell antigen 2 antibodies and uses thereofBIOGEN MA INC·Filed 2025·Application pending·0 cites
- 5065US2017174658A1Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Showing the top 50 of 71 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →